On February 14, 2018, the Risk Management Division of the Food and Drug Administration, Ministry of Health and Welfare of the Republic of China (TFDA), issued a notice regarding “SILYGEN-H CAPSULE 150MG (SILYMARIN) ‘H.C.’” manufactured by Ho Seng Pharmaceutical Chemical Co., Ltd. The manufacturer reported that the batch failed to meet weight variation specifications, prompting a voluntary recall following evaluation.
Basic Information of the Recalled Drug
- Drug / Product Name: SILYGEN-H CAPSULE 150MG (SILYMARIN) “H.C.”.
- Indications: Adjuvant therapy for chronic liver disease, cirrhosis, and fatty liver.
- Active Ingredient: SILYMARIN (EXSICCATED FRUCTUS CARDUI MARIANUS EXTRACT), an antioxidant and therapeutic compound extracted from milk thistle.
- License Number: MOHW Drug Manufacturing No. 038840.
- Batch Number: D1607034.
- License Holder: Ho Seng Pharmaceutical Chemical Co., Ltd.
Silygen-H Capsule (Website Screenshot / kmtth)
Drug Recall Details
- Recall Classification: Class 2[i].
- Recall Document Number: FDA Risk Management Division Doc No. 1070004778.
- Issue Date: February 14, 2018.
- Release Date: February 14, 2018.
- Reason for Recall: Drug weight variation results did not meet specifications; voluntary recall by the manufacturer.
Further Reading
Support Independent Perspectives & In-Depth Insights
Every thoughtful analysis and candid critique comes from our dedication to truth and quality. We choose not to follow sensational algorithms or clickbait headlines.
Sustaining independent research requires reader support. Make a one-time or monthly contribution, securely processed by Google.
Payments secured by Google · Manage or cancel anytime in your Google Account

Comments